BUSINESS

Xocova Makes Mark in PIII Study for Post-Exposure Prophylaxis: Shionogi

October 30, 2024
Shionogi said on October 29 that its oral COVID-19 treatment Xocova (ensitrelvir) hit the primary endpoint in a global PIII study evaluating the drug as a post-exposure prophylaxis (PEP). The double-blind, randomized, placebo-controlled study, dubbed SCORPIO-PEP, enrolled some 2,400 participants…

To read the full story

Related Article

BUSINESS

By Shunsuke Tani

Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…

Japan’s health ministry on November 16 approved AbbVie’s glabellar lines drug Boey (trenibotulinumtoxinE), along with a slate of label expansions…

By Shinya Sato

Japan’s push to expand biosimilar use is running into a troubling supply problem. All seven ingredients that made their biosimilar…

By Kohei Hori

A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…

By Hayate Horiguchi

A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…